Crunch time for the Spac space
This month has seen two blank-cheque company deals fall apart, and more terminations should be expected.
The lung fibrosis pipeline thins
This month Pliant Therapeutics claimed a win in idiopathic pulmonary fibrosis, but other projects have fallen by the wayside.
Gilead’s Galapagos hopes now rest on Toledo
Toxicity worries send yet another Gilead/Galapagos project, ziritaxestat, to the scrapheap.
Galapagos “win” highlights crowded idiopathic pulmonary fibrosis pipeline
Galapagos is betting big in IPF but others, including Fibrogen and Roche, are also taking aim at the lung disease.
